Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
62.92
+0.28 (0.45%)
At close: Feb 10, 2026, 4:00 PM EST
63.27
+0.35 (0.56%)
After-hours: Feb 10, 2026, 7:45 PM EST
Arrowhead Pharmaceuticals Employees
Arrowhead Pharmaceuticals had 711 employees as of September 30, 2025. The number of employees increased by 102 or 16.75% compared to the previous year.
Employees
711
Change (1Y)
102
Growth (1Y)
16.75%
Revenue / Employee
$1,534,432
Profits / Employee
$284,480
Market Cap
8.81B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 711 | 102 | 16.75% |
| Sep 30, 2024 | 609 | 84 | 16.00% |
| Sep 30, 2023 | 525 | 128 | 32.24% |
| Sep 30, 2022 | 397 | 68 | 20.67% |
| Sep 30, 2021 | 329 | 97 | 41.81% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bio-Techne | 3,100 |
| Jazz Pharmaceuticals | 2,800 |
| Axsome Therapeutics | 816 |
| Madrigal Pharmaceuticals | 528 |
| Cytokinetics | 498 |
| Vaxcyte | 414 |
| Halozyme Therapeutics | 350 |
| Krystal Biotech | 275 |
ARWR News
- 4 days ago - Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2026 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results - Business Wire
- 6 days ago - Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600 - PRNewsWire
- 14 days ago - Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia - Business Wire
- 21 days ago - Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results - Business Wire
- 4 weeks ago - Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants - Business Wire
- 4 weeks ago - Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China - Business Wire